Thrombotic Thrombocytopenic Purpura (TTP)
What is Thrombotic Thrombocytopenic Purpura (TTP)?
Thrombotic thrombocytopenic purpura is a rare blood disorder that creates tiny blood clots throughout your body. These clots form in small blood vessels and use up platelets, which are the cells that help your blood clot normally. When platelets get used up too quickly, your count drops dangerously low.
TTP is a medical emergency that requires immediate treatment. The clots can block blood flow to vital organs like your brain, heart, and kidneys. At the same time, the low platelet count puts you at risk for serious bleeding. This combination makes TTP life-threatening without prompt medical care.
TTP happens when an enzyme called ADAMTS13 stops working properly. This enzyme normally breaks down large clumps of a protein called von Willebrand factor. Without enough working ADAMTS13, these protein clumps trigger abnormal clot formation. Most cases develop suddenly in adults, though some people inherit a genetic form from birth.
Symptoms
- Purple or red spots on the skin called purpura
- Unusual bleeding or bruising that appears without injury
- Extreme fatigue and weakness
- Fever without a clear infection
- Headaches and confusion
- Difficulty speaking or understanding speech
- Vision changes or blurred vision
- Chest pain or rapid heartbeat
- Abdominal pain and nausea
- Dark or bloody urine
Some people develop symptoms gradually over days, while others experience sudden onset within hours. Early symptoms can seem vague like fatigue or fever, making TTP hard to recognize initially.
Concerned about Thrombotic Thrombocytopenic Purpura (TTP)? Check your levels.
Screen for 1,200+ health conditions
Causes and risk factors
Most TTP cases happen when your immune system mistakenly attacks the ADAMTS13 enzyme. This is called acquired TTP and can develop at any age. The exact trigger for this immune response often remains unknown. Some cases follow infections, pregnancy, certain medications, or autoimmune conditions. However, many people develop TTP without any clear cause.
A smaller percentage of cases are hereditary TTP, where people are born with mutations affecting the ADAMTS13 gene. Women face higher risk than men, especially during pregnancy or while using birth control pills. Cancer, HIV infection, bone marrow transplants, and some chemotherapy drugs also increase risk. People with autoimmune diseases like lupus have elevated TTP risk as well.
How it's diagnosed
Doctors diagnose TTP through blood tests that reveal the characteristic pattern of this condition. A platelet count shows severely low levels, often below 30,000 per microliter when normal is 150,000 to 400,000. Bilirubin levels rise because red blood cells break apart as they squeeze through clotted vessels. This destruction of red blood cells is called microangiopathic hemolysis. A blood smear under a microscope shows fragmented red blood cells called schistocytes.
Additional testing measures ADAMTS13 enzyme activity to confirm the diagnosis. Rite Aid offers testing for platelet count and bilirubin levels, which are key markers for detecting and monitoring TTP. Because TTP is a medical emergency, anyone with suspected symptoms needs immediate evaluation at a hospital. Early detection through blood testing saves lives by enabling rapid treatment.
Treatment options
- Plasma exchange therapy to remove harmful antibodies and replace missing ADAMTS13 enzyme
- Immunosuppressive medications like corticosteroids to reduce immune system activity
- Rituximab to target antibody-producing immune cells
- Caplacizumab to prevent platelet clumping during acute episodes
- Platelet transfusions are typically avoided as they can worsen clotting
- Treatment in an intensive care unit for severe cases
- Ongoing monitoring with regular blood tests during recovery
- Long-term follow-up to watch for relapse in acquired TTP
Most people with TTP need immediate hospitalization. Plasma exchange therapy is the primary treatment and must start as soon as possible. Without treatment, TTP is fatal in over 90 percent of cases. With proper treatment, survival rates exceed 80 percent. Recovery takes weeks to months, and some people experience relapses that require additional treatment.
Concerned about Thrombotic Thrombocytopenic Purpura (TTP)? Get tested at Rite Aid.
- Simple blood draw at your nearest lab
- Results in days, not weeks
- Share results with your doctor
Frequently asked questions
Without treatment, TTP is fatal in more than 90 percent of cases. With prompt plasma exchange therapy, survival rates improve dramatically to over 80 percent. Early diagnosis and immediate treatment are critical for good outcomes. Most people who receive treatment within the first few days make a full recovery.
TTP can develop very suddenly, with symptoms appearing within hours or days. Some people notice vague symptoms like fatigue for a few days before more serious signs develop. The condition progresses rapidly once it starts. Any combination of unusual bruising, confusion, fever, and fatigue requires immediate medical attention.
Yes, people with acquired TTP face a 30 to 60 percent risk of relapse. Relapses typically happen within the first year after initial treatment but can occur years later. Regular blood test monitoring helps catch relapses early. People who have had TTP should watch for any returning symptoms and seek immediate care.
About 5 to 10 percent of TTP cases are hereditary, caused by mutations in the ADAMTS13 gene. Most cases are acquired, meaning they develop due to immune system problems rather than genetics. Hereditary TTP usually appears in infancy or childhood. Acquired TTP typically develops in adults with no family history.
TTP typically causes platelet counts below 30,000 per microliter, well below the normal range of 150,000 to 400,000. Many people with TTP have counts below 20,000. The severely low platelet count combined with other blood test findings helps confirm the diagnosis. Platelet levels are monitored daily during treatment.
Bilirubin increases because red blood cells break apart when they pass through blood vessels blocked by tiny clots. This destruction releases hemoglobin, which your body converts to bilirubin. The liver cannot process bilirubin fast enough when many cells break at once. Elevated bilirubin is a key sign of the hemolytic anemia that occurs in TTP.
There is no proven way to prevent first-time TTP episodes because the trigger is often unknown. People who have had TTP should avoid known triggers like certain medications. Some doctors prescribe low-dose rituximab to prevent relapses in high-risk individuals. Regular monitoring with blood tests helps detect problems early before they become severe.
Plasma exchange therapy typically continues daily until platelet counts return to safe levels, usually 7 to 14 days. Some people need treatment for several weeks. Immunosuppressive medications may continue for months after plasma exchange stops. Complete recovery takes weeks to months, and monitoring continues for at least a year to watch for relapse.
The exact trigger remains unknown in many cases of acquired TTP. Known triggers include certain infections, pregnancy, medications like chemotherapy or immunosuppressants, and autoimmune diseases. Some cases develop after bone marrow transplants or cancer treatment. In roughly half of cases, no clear trigger is identified despite thorough investigation.
Pregnancy is a known risk factor for TTP, particularly in the third trimester or shortly after delivery. Women who have had TTP before face higher risk during pregnancy. Pregnancy-related TTP requires careful management by specialists in high-risk obstetrics. Women with a history of TTP should discuss risks with their doctor before becoming pregnant.